Investors

Webcast ImageWebcast
Depomed at the 2015 JMP Securities Life Sciences Conference  (Replay)
06/23/15 at 10:00 a.m. ET
Download Event Supporting Material  NUCYNTA Acquisition Investor Presentation

Depomed is a specialty pharmaceutical company focused on pain and other central nervous system conditions. We currently market FDA-approved products, NUCYNTA®ER, NUCYNTA®, Gralise®, Cambia®, Lazanda® and Zipsor®. We actively seek to expand our product portfolio by identifying product acquisition targets that fit within our pain and neurology portfolio, have lengthy periods of exclusivity and have untapped market potential.Depomed also has successfully developed and licensed its proprietary oral drug-delivery technology, Acuform®, that allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. Depomed has licensed Acuform technology to six pharmaceutical partners, and the technology is currently being used in four marketed drugs, including NUCYNTA ER and Gralise.

The following are abbreviated descriptions of Depomed’s products:

NUCYNTA® ER (tapentadol) extended release tablets indicated, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate and in adult patients who have neuropathic pain associated with diabetic peripheral neuropathy (DPN) that is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate;

NUCYNTA® (tapentadol) an immediate release version of tapentadol, is indicated for the management of moderate to severe acute pain in adults;

Gralise® (gabapentin), a once-daily product for the management of postherpetic neuralgia, 

Cambia®(diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older,

Lazanda® (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving and who are tolerant to regular opioid therapy for their underlying persistent cancer pain, and

Zipsor® (diclofenac potassium) liquid filled capsules, a product for the treatment of mild to moderate acute pain in adults.

See Important Safety Information for Gralise and the black box warnings for NUCYNTA ER, NUCYNTA, Cambia, Lazanda and Zipsor.

Recent News> MORE
DateTitle 
06/17/15Depomed Announces Change To Presentation Time At JMP Life Sciences ConferencePrinter Friendly Version
06/03/15Depomed Announces Zipsor® ANDA Litigation Settlement Providing for Exclusivity to March 2022Printer Friendly Version
05/26/15Depomed To Present At Healthcare Conferences In JunePrinter Friendly Version
Upcoming and Recent Events> MORE
DateTitle
06/23/15
10:00 a.m. ET
Depomed at the 2015 JMP Securities Life Sciences Conference
LocationNew York, NY
Supporting Materials
Download Event Supporting Material JMP Securities Life Sciences Conference 2015 Presentation
06/02/15
3:00 p.m. ET
Depomed at the 2015 Jefferies Healthcare Conference
LocationNew York, NY
Supporting Materials
Download Event Supporting Material Jefferies Healthcare Conference Presentation
05/20/15
8:30 a.m. ET
Depomed at the UBS 2015 Global Healthcare Conference
LocationNew York, NY

DEPO (Common Stock)

Exchange
NASDAQ CM
Price
$20.84
Change (%)
 - 0.02 (0.10%)
Volume
626,455
Market Cap
$1,249,628,920

Data as of 07/02/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Powered By EDGAR Online, Inc.